Skip to main content

Highlight Capital — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

79
Companies
$2.2B
Total invested
$28.8M
Avg. check
33
Industries
Medical 11Biotechnology 10Health Care 9Biopharma 5Pharmaceutical 5Therapeutics 4+27 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 79
Nuclidium
May 2026

Nuclidium is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics.

Health Care · Basel$33.6M Series B
Allegria Therapeutics
April 2026

Allegria Therapeutics is a biotech firm that engages in the research and treatment of allergy and mast cell-mediated inflammatory diseases.

Biotechnology · Basel$1.5M Grant
ImageneBio
April 2026

ImageneBio is dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases

Biopharma · San Diego$30.0M Post-IPO Equity
Vivatides Therapeutics
April 2026

Vivatides Therapeutics develops RNA treatments to help improve patients' lives using biotechnology research.

Biotechnology · Woburn$54.0M Series A
T-CURX
December 2025

T-CURX develops personalized T cell therapies for cancer, leveraging a proprietary platform for improved patient outcomes.

Biotechnology · Würzburg$20.0M Series A
Ultra Social
October 2025

Ultra Social is a AI company that builds generative AI-powered digital human and social media marketing solutions.

Digital Marketing · Sarugakucho$7.6M Series B
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Nuevocor
May 2025

Nuevocor operates as a preclinical-stage biotech company.

Biopharma · Singapore$45.0M Series B
Rgenta Therapeutics
May 2023

Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology.

Biotechnology · Cambridge$8.0M Series A
Cullgen
May 2023

Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.

Biotechnology · San Diego$35.0M Series C
SparX Group
December 2021

SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates.

Biopharma · Grand Cayman$30.0M Series B
Spirit AI
February 2026

Spirit AI builds 'universal brain' for real-world robots.

Artificial Intelligence (AI) · Beijing$290.0M Series A
Yiteng Medical
January 2026

Yiteng Medical is a medical technology company that manufactures imaging components and medical device parts used in diagnostic systems.

Health Diagnostics · Suzhou$14.4M Series A
Spurious
January 2026

Spurious is the developer of the small molecule anti-tumordrug developers.

Health Care · Shanghai$35.0M Seed
Realm of Illumination
January 2026

Realm of Illumination is an AI smarter hardware company that specializes in R&D for AI smart terminal equipment.

Artificial Intelligence (AI)Seed
Shouxing Technology
December 2025

Shouxing Technology is the developer of the Humanoid robot.

Robotics · New CitySeries Unknown
Novachip Microelectronics
November 2025

Novachip Microelectronics is a provider of optoelectronic interconnect chips, focusing on the R&D and sales of such chips.

Energy · Hangzhou$14.1M Angel
USUN BIO
October 2025

USUN BIO is a drug research and development company.

Biotechnology · JiangyinSeries Unknown
AsiaSonic Semiconductor
October 2025

AsiaSonic Semiconductor focuses on three main pan-semiconductor sectors: integrated circuits, displays, and photovoltaics.

Machinery Manufacturing · Hefei$14.0M Series B
Yuansheng Intelligence
September 2025

Yuansheng Intelligence is a manufacturer of intricate rehabilitation and nursing medical hardware.

Manufacturing · DongguangAngel
Sieran Medical
September 2025

Sieran Medical is a medical device company that specializes in minimally invasive surgical treatment solutions for ophthalmology.

Medical · Suzhou$14.0M Series Unknown
E-nitiate Biopharmaceuticals
September 2025

E-nitiate Biopharmaceuticals is committed to the development of innovative drugs for autoimmune diseases, through independent research.

Biopharma · Hangzhou$28.0M Series B
Ennovabio
September 2025

Ennovabio is a Chinese drug developer that focuses on creating drugs targeting brain glioma.

Biopharma · ShanghaiSeries Unknown
XINGYUN GROUP
August 2025

Xingyun Group comprehensive services platform for global commodities.

B2B · ShenzhenSeries Unknown

Where Highlight Capital invests

Medical11
Biotechnology10
Health Care9
Biopharma5
Pharmaceutical5
Therapeutics4

About Highlight Capital's portfolio

How many companies has Highlight Capital invested in?▸

Highlight Capital has invested in 79 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Highlight Capital invest in?▸

Highlight Capital's top investment sectors include Medical, Biotechnology, Health Care, Biopharma, Pharmaceutical. The firm invests across 33 different industry categories.

What is Highlight Capital's largest investment?▸

Among tracked funding rounds, Spirit AI received $290.0M in a Series A round. Highlight Capital's total known invested capital is $2.2B.

What is the average investment size for Highlight Capital?▸

Highlight Capital's average investment size is $28.8M across its portfolio of 79 companies.

What are Highlight Capital's most recent investments?▸

Recent Highlight Capital portfolio additions include Nuclidium, Allegria Therapeutics, ImageneBio, Vivatides Therapeutics, T-CURX. These companies were founded in 2020 or later.

Reach the founders behind these 79 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →